Tyrosine phosphorylation in Toll-like receptor signaling

Cytokine and Growth Factor Reviews

Volumn 25, Issue 5, 2014, Pages 533-541

  Chattopadhyay, Saurabh ^a   Sen, Ganes C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

EGFR; Protein tyrosine kinases; Src; TLR; Tyrosine phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN TYROSINE KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TYROSINE;

AUTOIMMUNITY; CELLULAR DISTRIBUTION; CROHN DISEASE; CYTOPLASM; GENE MUTATION; GENETIC POLYMORPHISM; HELICOBACTER PYLORI; HUMAN; INFECTION SENSITIVITY; LEPROSY; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; ULCERATIVE COLITIS; ANIMAL; BIOLOGICAL MODEL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TYROSINE;

EID: 84908339164     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.06.002     Document Type: Short Survey

References (90)

1. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
2. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
3. McGettrick A.F., O'Neill L.A. Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr Opin Immunol 2010, 22:20-27.
4. Johnson P., Cross J.L. Tyrosine phosphorylation in immune cells: direct and indirect effects on Toll-like receptor-induced proinflammatory cytokine production. Crit Rev Immunol 2009, 29:347-367.
5. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
6. Nishiya T., Kajita E., Miwa S., Defranco A.L. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005, 280:37107-37117.
7. Kim Y.M., Brinkmann M.M., Paquet M.E., Ploegh H.L. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 2008, 452:234-238.
8. Garcia-Cattaneo A., Gobert F.X., Muller M., Toscano F., Flores M., Lescure A., et al. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc Natl Acad Sci U S A 2012, 109:9053-9058.
9. Oldenburg M., Kruger A., Ferstl R., Kaufmann A., Nees G., Sigmund A., et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012, 337:1111-1115.
10. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
11. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
12. Tsung A., Klune J.R., Zhang X., Jeyabalan G., Cao Z., Peng X., et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007, 204:2913-2923.
13. Rohde D., Schon C., Boerries M., Didrihsone I., Ritterhoff J., Kubatzky K.F., et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. EMBO Mol Med 2014, 6:778-794.
14. Barton G.M., Kagan J.C. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009, 9:535-542.
15. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
16. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003, 301:640-643.
17. Jabara H.H., McDonald D.R., Janssen E., Massaad M.J., Ramesh N., Borzutzky A., et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012, 13:612-620.
18. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
19. Hoshino K., Sugiyama T., Matsumoto M., Tanaka T., Saito M., Hemmi H., et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006, 440:949-953.
20. Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X. Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6 (TRAF6) complex. J Biol Chem 2003, 278:10952-10956.
21. Lin R., Heylbroeck C., Pitha P.M., Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998, 18:2986-2996.
22. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 2007, 282:15325-15329.
23. Yang P., An H., Liu X., Wen M., Zheng Y., Rui Y., et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 2010, 11:487-494.
24. Chattopadhyay S., Fensterl V., Zhang Y., Veleeparambil M., Wetzel J.L., Sen G.C. Inhibition of viral pathogenesis and promotion of the septic shock response to bacterial infection by IRF-3 are regulated by the acetylation and phosphorylation of its coactivators. mBio 2013, 4.
25. Pasare C., Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003, 15:677-682.
26. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9:57-63.
27. Netea M.G., Wijmenga C., O'Neill L.A. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 2012, 13:535-542.
28. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010, 9:293-307.
29. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
30. Kang T.J., Chae G.T. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001, 31:53-58.
31. Ogus A.C., Yoldas B., Ozdemir T., Uguz A., Olcen S., Keser I., et al. The Arg753GLn polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004, 23:219-223.
32. Xiong Y., Song C., Snyder G.A., Sundberg E.J., Medvedev A.E. R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88. J Biol Chem 2012, 287:38327-38337.
33. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007, 39:523-528.
34. Ku C.L., von Bernuth H., Picard C., Zhang S.Y., Chang H.H., Yang K., et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007, 204:2407-2422.
35. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.
36. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
37. Paone A., Galli R., Gabellini C., Lukashev D., Starace D., Gorlach A., et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia 2010, 12:539-549.
38. Yang Z., Stratton C., Francis P.J., Kleinman M.E., Tan P.L., Gibbs D., et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008, 359:1456-1463.
39. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
40. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032.
41. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 2003, 4:471-477.
42. Siegfried A., Berchtold S., Manncke B., Deuschle E., Reber J., Ott T., et al. IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-alpha secretion and LPS-induced endotoxin shock. J Immunol 2013, 191:3913-3921.
43. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000, 68:7010-7017.
44. Ishizuka F., Shimazawa M., Inoue Y., Nakano Y., Ogishima H., Nakamura S., et al. Toll-like receptor 4 mediates retinal ischemia/reperfusion injury through nuclear factor-kappaB and spleen tyrosine kinase activation. Invest Ophthalmol Vis Sci 2013, 54:5807-5816.
45. Celhar T., Magalhaes R., Fairhurst A.M. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012, 53:58-77.
46. Yamashita M., Chattopadhyay S., Fensterl V., Saikia P., Wetzel J.L., Sen G.C. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal 2012, 5:ra50.
47. Johnsen I.B., Nguyen T.T., Ringdal M., Tryggestad A.M., Bakke O., Lien E., et al. Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling. EMBO J 2006, 25:3335-3346.
48. Sarkar S.N., Smith H.L., Rowe T.M., Sen G.C. Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J Biol Chem 2003, 278:4393-4396.
49. Sarkar S.N., Peters K.L., Elco C.P., Sakamoto S., Pal S., Sen G.C. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol 2004, 11:1060-1067.
50. Sarkar S.N., Elco C.P., Peters K.L., Chattopadhyay S., Sen G.C. Two tyrosine residues of Toll-like receptor 3 trigger different steps of NF-kappa B activation. J Biol Chem 2007, 282:3423-3427.
51. Hsieh M.Y., Chang M.Y., Chen Y.J., Li Y.K., Chuang T.H., Yu G.Y., et al. The inducible nitric-oxide synthase (iNOS)/Src axis mediates Toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-beta synthesis in macrophages. J Biol Chem 2014, 289:9208-9220.
52. Lee K.G., Xu S., Kang Z.H., Huo J., Huang M., Liu D., et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci U S A 2012, 109:5791-5796.
53. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002, 3:667-672.
54. Zanoni I., Ostuni R., Marek L.R., Barresi S., Barbalat R., Barton G.M., et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 2011, 147:868-880.
55. Yamamoto M., Sato S., Hemmi H., Uematsu S., Hoshino K., Kaisho T., et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003, 4:1144-1150.
56. Kagan J.C., Su T., Horng T., Chow A., Akira S., Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008, 9:361-368.
57. Chen L.Y., Zuraw B.L., Zhao M., Liu F.T., Huang S., Pan Z.K. Involvement of protein tyrosine kinase in Toll-like receptor 4-mediated NF-kappa B activation in human peripheral blood monocytes. Am J Physiol Lung Cell Mol Physiol 2003, 284:L607-L613.
58. Smolinska M.J., Horwood N.J., Page T.H., Smallie T., Foxwell B.M. Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages. Mol Immunol 2008, 45:990-1000.
59. Medvedev A.E., Piao W., Shoenfelt J., Rhee S.H., Chen H., Basu S., et al. Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem 2007, 282:16042-16053.
60. Avila M., Martinez-Juarez A., Ibarra-Sanchez A., Gonzalez-Espinosa C. Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells. Innate Immun 2012, 18:648-660.
61. Jefferies C.A., Doyle S., Brunner C., Dunne A., Brint E., Wietek C., et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 2003, 278:26258-26264.
62. Miller Y.I., Choi S.H., Wiesner P., Bae Y.S. The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL. Br J Pharmacol 2012, 167:990-999.
63. Lin Y.C., Huang D.Y., Chu C.L., Lin Y.L., Lin W.W. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3. Sci Signal 2013, 6:ra71.
64. Lu N., Wang L., Cao H., Liu L., Van Kaer L., Washington M.K., et al. Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol 2014, 192:1013-1023.
65. Arbibe L., Mira J.P., Teusch N., Kline L., Guha M., Mackman N., et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 2000, 1:533-540.
66. Ha T., Hu Y., Liu L., Lu C., McMullen J.R., Kelley J., et al. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2010, 87:694-703.
67. Horwood N.J., Page T.H., McDaid J.P., Palmer C.D., Campbell J., Mahon T., et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006, 176:3635-3641.
68. Ivison S.M., Khan M.A., Graham N.R., Bernales C.Q., Kaleem A., Tirling C.O., et al. A phosphorylation site in the Toll-like receptor 5 TIR domain is required for inflammatory signalling in response to flagellin. Biochem Biophys Res Commun 2007, 352:936-941.
69. Rajagopal R., Waller A.S., Mendoza J.D., Wightman P.D. The covalent modification and regulation of TLR8 in HEK-293 cells stimulated with imidazoquinoline agonists. Biochem J 2008, 409:275-287.
70. Lee K.G., Xu S., Wong E.T., Tergaonkar V., Lam K.P. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem 2008, 283:11189-11198.
71. Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A. Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem 2007, 282:36953-36960.
72. Sanjuan M.A., Rao N., Lai K.T., Gu Y., Sun S., Fuchs A., et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 2006, 172:1057-1068.
73. Chockalingam A., Rose W.A., Hasan M., Ju C.H., Leifer C.A. Cutting edge: a TLR9 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine production. J Immunol 2012, 188:527-530.
74. Gray P., Dagvadorj J., Michelsen K.S., Brikos C., Rentsendorj A., Town T., et al. Myeloid differentiation factor-2 interacts with Lyn kinase and is tyrosine phosphorylated following lipopolysaccharide-induced activation of the TLR4 signaling pathway. J Immunol 2011, 187:4331-4337.
75. Piao W., Song C., Chen H., Wahl L.M., Fitzgerald K.A., O'Neill L.A., et al. Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J Biol Chem 2008, 283:3109-3119.
76. Gray P., Dunne A., Brikos C., Jefferies C.A., Doyle S.L., O'Neill L.A. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 2006, 281:10489-10495.
77. Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006, 7:148-155.
78. Han C., Jin J., Xu S., Liu H., Li N., Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 2010, 11:734-742.
79. Jiao H., Zhang Y., Yan Z., Wang Z.G., Liu G., Minshall R.D., et al. Caveolin-1 Tyr14 phosphorylation induces interaction with TLR4 in endothelial cells and mediates MyD88-dependent signaling and sepsis-induced lung inflammation. J Immunol 2013, 191:6191-6199.
80. Stacey K.B., Breen E., Jefferies C.A. Tyrosine phosphorylation of the E3 ubiquitin ligase TRIM21 positively regulates interaction with IRF3 and hence TRIM21 activity. PLoS ONE 2012, 7:e34041.
81. Yamashita M., Chattopadhyay S., Fensterl V., Zhang Y., Sen G.C. A TRIF-independent branch of TLR3 signaling. J Immunol 2012, 188:2825-2833.
82. Burtness B., Marur S., Bauman J.E., Golemis E.A., Mehra R., Cohen S.J. Comment on "epidermal growth factor receptor is essential for Toll-like receptor 3 signaling". Sci Signal 2012, 5:lc5.
83. Basu S., Pathak S.K., Chatterjee G., Pathak S., Basu J., Kundu M. Helicobacter pylori protein HP0175 transactivates epidermal growth factor receptor through TLR4 in gastric epithelial cells. J Biol Chem 2008, 283:32369-32376.
84. McElroy S.J., Hobbs S., Kallen M., Tejera N., Rosen M.J., Grishin A., et al. Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS ONE 2012, 7:e38373.
85. Mustelin T., Vang T., Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 2005, 5:43-57.
86. An H., Zhao W., Hou J., Zhang Y., Xie Y., Zheng Y., et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 2006, 25:919-928.
87. An H., Hou J., Zhou J., Zhao W., Xu H., Zheng Y., et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008, 9:542-550.
88. Zhang P., Liu X., Li Y., Zhu X., Zhan Z., Meng J., et al. Protein tyrosine phosphatase with proline-glutamine-serine-threonine-rich motifs negatively regulates TLR-triggered innate responses by selectively inhibiting IkappaB kinase beta/NF-kappaB activation. J Immunol 2013, 190:1685-1694.
89. Lu R., Pan H., Shively J.E. CEACAM1 negatively regulates IL-1beta production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog 2012, 8:e1002597.
90. Yan D., Wang X., Luo L., Cao X., Ge B. Inhibition of TLR signaling by a bacterial protein containing immunoreceptor tyrosine-based inhibitory motifs. Nat Immunol 2012, 13:1063-1071.